Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05793853 · ClinicalTrials.gov registry record
Hypoparathyroidism Natural History Study
A clinical trial of Hypoparathyroidism, sponsored by Columbia University.
- Recruiting
- Registry status
- 106
- Enrollment target
- 1
- Study location
NCT05793853: Recruiting study of Hypoparathyroidism, sponsored by Columbia University.
NCT05793853 is a study of Hypoparathyroidism that is actively recruiting participants, run by Columbia University. The registered enrollment target is 106 participants, below the 189-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05793853, a study of Hypoparathyroidism, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 106 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective three-year natural history study of adults with hypoparathyroidism. The goal is to monitor patients with hypoparathyroidism to define end-organ damage in the context of the disease. The study objectives are to: 1. Build a prospective cohort of patients to study HPT-associated end-organ damage. 2. Determine end-organ physiologic consequences of HPT. 3. Elucidate determinants of HPT-associated end-organ damage. Funding Source - FDA OOPD
Primary Outcome
blood test for changes in eGFR (in mL/min/1.73m\^2)
Conditions Studied
Study Locations (1)
New York
- Columbia University Medical Center - Harkness Pavillion - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2022-08-25 |
| Est. Completion | 2026-12 |
What NCT05793853 shows while recruiting
NCT05793853 is an observational study that tracks outcomes without assigning an intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 189-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Hypoparathyroidism appearing as the primary indexed condition, and to 0 interventions.
NCT05793853 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05793853 about?
NCT05793853 is a clinical study titled "Hypoparathyroidism Natural History Study". This is a prospective three-year natural history study of adults with hypoparathyroidism. The goal is to monitor patients with hypoparathyroidism to define end-organ damage in the context of the disease. The study objectives are to: 1. Build a prospective cohort of patients to study HPT-associated...
What is the current status of trial NCT05793853?
This trial is currently recruiting. The enrollment target is 106 participants. The study started on 2022-08-25. Estimated completion is 2026-12.
What conditions does trial NCT05793853 study?
This clinical trial studies the following conditions: Hypoparathyroidism.
Who is sponsoring clinical trial NCT05793853?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05793853 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05793853's enrollment target sits among peer trials
106 3rd of 10 higher than 8 of 10 other Hypoparathyroidism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoparathyroidism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
RECRUITING · Phase 1
-
A Registry for Participants With Chronic Hypoparathyroidism
ACTIVE NOT RECRUITING
-
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
ACTIVE NOT RECRUITING · Phase 2
-
Use of NPSP558 in the Treatment of Hypoparathyroidism
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI